Optimising antifungal therapy for individual patients

Internal Medicine Journal

Volumn 34, Issue 4, 2004, Pages 147-149

  Hope, W W ^a   Denning, D W ^a  

^a WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CYCLODEXTRIN; CYTOCHROME P450 2C19; ECHINOCANDIN B; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; PYRROLE; RAVUCONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; CENTRAL VENOUS CATHETER; DISEASE DURATION; DRUG CHOICE; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; DRUG TOLERABILITY; EDITORIAL; ENZYME POLYMORPHISM; FEBRILE NEUTROPENIA; FUNGAL MENINGITIS; FUSARIUM; HUMAN; KIDNEY FAILURE; LIVER DYSFUNCTION; MORTALITY; MUCORMYCOSIS; MYCOLOGY; MYCOSIS; NONLINEAR SYSTEM; PRIORITY JOURNAL; RASH; RETINA DISEASE; SIDE EFFECT; TOTAL PARENTERAL NUTRITION; TREATMENT FAILURE; YEAST; ZYGOMYCETES;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CLINICAL TRIALS; HUMANS; MYCOSES; PRACTICE GUIDELINES;

EID: 2442580826     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1444-0903.2004.00569.x     Document Type: Editorial

References (24)

1. Slavin MA, Szer J, Grigg AP, Roberts AW, Seymour JF, Sasadeusz J et al. Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. Intern Med J, 2004; 34: 192-200.
2. Cornely OA, Bohme A, Buchheidt D, Glasmacher A, Kahl C, Karthaus M et al. Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumours - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82: S186-200.
3. Link H, Blumenstengel K, Bohme A, Cornely O, Kellner O, Nowrousian MR et al. [Antimicrobial therapy for fever of unknown origin in neutropenia. Standard recommendations of the Work Group of Infections in Hematology and Oncology of the German Association of Hematology and Oncology]. Dtsch Med Wochenschr 1999; 124: S3-8.
4. Maschmeyer G, Beinert T, Buchheidt D, Einsele H, Heussel CP, Kiehl M et al. Diagnosis and antimicrobial therapy of pulmonary infiltrates in febrile neutropenic patients - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82: S118-26.
5. Bohme A, Ruhnke M, Buchheidt D, Karthaus M, Einsele H, Guth S et al. Treatment of fungal infections in hematology and oncology - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82: S133-40.
6. Denning DW, Kibbler CC, Barnes RA. British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. Lancet Infect Dis 2003; 3: 230-40.
7. Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 696-709.
8. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001; 32: 686-93.
9. Wingard JR, Kubilis P, Lee L, Yee G, White M, Walshe L et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999; 29: 1402-7.
10. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
11. Food and Drug Administration. Background document for the Antiviral Drug Products Advisory Committee Meeting, 4 October 2001. Food and Drug Administration, Center for Drug Evaluation and Research, Division of Special Pathogen and Immunologic Drug Products [cited 11 Dec 2003]. Available from: URL: htp://http://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2_02_FDA- voriconazole.pdf
12. Karthaus M. Voriconazole versus amphotericin B for invasive aspergillosis. N Engl J Med 2002; 347: 2080-81.
13. Bowden R, Chandrasekar P, White MH, Li X, Pietrelli L, Gurwith M et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35: 359-66.
14. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142-51.
15. Denning DW, Lee JY, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH et al. NIAID Mycoses Study Group Multicenter Trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994; 97: 135-44.
16. Stevens DA & Lee JY. Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NAID Mycoses Study Group criteria. Arch Intern Med 1997; 157: 1857-62.
17. Walsh T, Sable C, Depauw B, Donowitz G, Maertens J, Baden L et al. Abstract M-1761. A randomized, double-blind, multicentre trial of caspofungin v liposomal amphotericin B for empirical antifungal therapy of persistently febrile neutropenic patients. Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003; Chicago, USA.
18. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546-54.
19. McNeil MM, Nash SL, Hajjeh RA, Phelan MA, Conn LA, Plikaytis BD et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001; 33: 641-7.
20. Kibbler CC, Seaton S, Barnes RA, Gransden WR, Holliman RE, Johnson EM et al. Management and outcome of bloodstream infections due to Candida species in England and Wales. J Hosp Infect 2003; 54: 18-24.
21. Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003; 36: 1221-8.
22. Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994; 331: 1325-30.
23. Phillips P, Shafran S, Garber G, Rotstein C, Smaill F, Fong I et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis 1997; 16: 337-45.
24. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-9.